|
|||||
|
|
Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma |
|
| Authors: | Frederick B. Stehman John A. Blessing Howard D. Homesley John L. Currie Edgardo L. Yordan |
| Affiliation: | (1) Indiana University Medical Center, Indianapolis, Indiana, USA;(2) Roswell Park Memorial Institute, Buffalo, New York, USA;(3) Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina, USA;(4) University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA;(5) Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, USA |
| Abstract: | Summary In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable. |
| Keywords: | galactitol dianhydrogalactitol cervix non-squamous-chemotherapy |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |